Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

COACH / CAM REVIEW > HEME > Flashcards

HEME Flashcards

1
Q

Factor common pathway and one drug acts here

A

factor 10

heparin anti-factor Xa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

trigger of the extrinsic pathway

A

tissue thromboplastin outside of the vessel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

trigger of the intrinsic pathway

A

collagen exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

diseases of the intrinsic pathway

A

hemophilia A. and B.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

how is factor XIII related to clot

A

measured by area clot stability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

primary factor that pro time measures

A

factor VII

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how dose deficiency in protein C and S. present

A

blood clots at young age

Minor risk factors create DVT

thrombus more commonly than factor V Leiden deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

workup for patient with multiple abortions

A

anticardiolipin antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

findings with anticardiolipin antibody

A

only procoagulants screening test

multiple portions

Increase in PTT and procoagulant screening test positive the

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

major test positive with hemophilia A. and B.

A

PTT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

percentage of hemophilia factor and needed for major Versus minor surgery

A

Cardiovascular, prostate, neurosurgery:

Greater than 100% x3 days
80%-100% x4-7 days
Greater than 50% for 8-14 days

Marjor:
80-100%
for 3 days then greater than 50% for next 7-11 days

minor:
greater than 50% for 3-7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

description and interpretation of mixing study correction studies her lupus

A

normal serum added to patient

does not correct: Negative
does not correct is good

Corrects with normal plasma: Positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

most common hypocoagulable condition

A

von Willebrand’s disease
bleeding time up
( possible increase in PTT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

mechanism of von Willebrand disease

A

prevent factor VIII from activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

von Willebrand’s disease the does not correct with DDAVP

A

von Willebrand 3

missing factor endothelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

treatment of von Willebrand disease

A

cryoprecipitate

DDAVP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

preop treatment of uremia

A

dialysis

DDAVP during surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

treatment to reverse Coumadin right away and efficacy

A

FFP

six-hour efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

major mechanism of heparin

A

acts on thrombin
factor 10
heparin is toanti-factor Xa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what lab values his warfarin effect

A

PT elevated

possible effect also on PTT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Ribaroxaban

A

Xarelto

irreversible heparin-like mechanism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Dabigatran

A

Pradaxa

warfarin-like mechanism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Hyper homocystinemia Defined, severity, treatment

A

20 times more blood clots and any other hypercoagulable disease

Most dangerous

Treatment:
folic acid
B12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

differential diagnosis with arterial thrombus and findings

A

hyper homocystinemia

HIT - have been induced thrombocytopenia
white clot-represent clumped platelets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

prothrombin factor

A

II

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

thrombin factor

A

IIa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

potential coagulopathy from prostate surgery

A

DIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

treatment DIC

A

Amicar

Aminocaproics acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

HIT time course

A

5-7 days from first exposure

mins - hrs from second exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Argatrobam mech

A

Leach

Shorter half-life

Liver cleared

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

blood product with highest infection rate

A

platelets

highest infection contaminant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

How much does 6 pack race platelet count

A

sixpack 50,000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

storage time of packed cells

A

the 42 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

increase hematocrit with one unit

A

3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

hematocrit with a hemoglobin of 7

A

21

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

factor 7a for trauma

A

no

Antithrombotic-intracranial bleed

37
Q

Xigris indications

A

none

pulled for market

prevent clot from activated protein C

38
Q

most common infection from transfusion

A

CMV

39
Q

hepatitis C. risk transfusion

A

one-2 million

can test for antigen

40
Q

hepatitis B risk transfusion

A

one-200,000

test for antiBODY

41
Q

coagulation complications from antibiotics

A

protein C deficiency

Pro time

Extrinsic pathway

42
Q

Liver disease coagulopathy

A

vitamin K

Viable

Prothrombin time

43
Q

Complications with rapid protamine administration and use

A

heparin reversal

Can get anaphylaxis from sensitivity with prior use of NPH insulin

44
Q

first blood consistent deficit with massive transfusion

A

decreased platelets

causes for symptoms of hypo-coagulation

45
Q

current recommendations for massive transfusion ratio

A

1:1:1
1 unit PRBC (not 2)
1 (SIXpack) of platelets
1 FFP

46
Q

cause of hypocalcemia with massive transfusion

A

citrate is bound with calcium

47
Q

acid-base pathology with massive transfusion

A

ALKOalotic
citrate down to bicarbonate
result is similar to contraction alkalosis

separate issue from acidosis with massive blood loss

48
Q

findings of contraction alkalosis

A 
dehydration-
hypovolemia-
increased sodium retention-
decreased potassium-
 responsive loss of hydrogen for exchange
49
Q

needle stick protocol

A

test patient
2 agent antiretroviral if high viral load
use is alternative drugs from patient

50
Q

coagulation finding with Bernard Soulier syndrome

A

congenital platelet dysfunction

GPIIb/IIIa

51
Q

Storage pool disease

A

congenital platelet dysfunction

defect in granules storage

52
Q

coagulation defect with mucosal bleeding epistaxis petechiae

A

platelet

53
Q

preoperative platelet count goal for most surgeries and exception

A

most surgeries 50,000

Spinal surgery 100,000

54
Q

hemophilia A. and B. laboratory abnormality

A

PTT

55
Q

von Willebrand disease lab abnormality

A

increased (or norm) bleeding time

Possible increased PTT

56
Q

factor VII deficiency Laboratory findings

A

PT elevated

57
Q

heparin laboratory findings

A

PTT elevated

58
Q

ow molecular weight heparin laboratory findings

A

PTT elevated

59
Q

DIC laboratory findings

A

elevated:
PTT, PT, bleeding time

decreased:
Platelets
Fibrinogen

positive split products

60
Q

liver disease coagulation laboratory findings

A

elevated:
PTT, PT bleeding time

Decrease: Platelets
Fibrinogen

61
Q

lupus anticoagulant laboratory findings

A

elevated:
PTT*
PT +/-
bleeding time

decrease:
Platelets

62
Q

Bernard-Soulier syndrome cause and laboratory findings, treatment

A

drugs:
Aspirin / NSAIDS
Ticlopidine
Clopidogrel

Mechanism:
GP IIB/IIIA Platelet dysfunction with

 treatment:
DDAVP
aprotinin
e-aminocaproic acid
Platelet transfusion
63
Q

vitamin deficiencies that can cause platelet decrease

A

B12
Folate

B12 also cause macrocytic anemia

64
Q

treatment of cardiopulmonary bypass coagulation defect

A

platelets are chewed up

Treatment:
DDAVP
aprotinin
e-aminocaproic acid
Platelet transfusion
65
Q

First choice of treatment for von Willebrand’s disease with elective scheduled surgery for optimization

A

DDAVP
Or
Von Willebrand factor concentrating factor VIII (Humate P)

or
Cryo

major:
50-100% 7-14 days

Minor:
greater than 50% one-3 days

66
Q

Factor V deficiency preoperative optimization

A

FFP
OR
prothrombin complex concentrates

major colon
Greater than 50%
Didn’t greater than 30%

Minor:
Greater than 15%

67
Q

prothrombin deficiency preoperative optimization

A

FFP
OR
prothrombin complex concentrates

68
Q

treatment of hypofibrinogenemia

A

cryoprecipitate

69
Q

constituents of cryoprecipitate and disadvantages

A

higher infectious risk than von Willebrand factor factor VIII concentrate

 contained:
Factor VIII
Von Willebrand factor
Fibrinogen
Factor XIII
70
Q

what is in fibrin sealant

A

fibrinogen
Thrombin
Factor 13

Huge for hemostasis

71
Q

mechanism of e-Aminocaproic acid and Aprotinin

A

antibiotic fibriolytic agents

inhibit fibrinolysis by inhibiting plasmin activity or generation

72
Q

mechanism desmopressin

A

releases of von Willebrand factor and factor VIII

Used for mild von Willebrand and factor VIII deficiency

73
Q

Lepirudin

A

recombinant direct thrombin inhibitor

Used for heparin-induced thrombocytopenia

Monitor with PTT

Extremities by kidneys

Half lipoma 0.3 hours

NO REVERSAL AGENT

74
Q

Bivalrudin

A

synthetic direct thrombin inhibitor

alternatives to heparin for cardiac procedures

no reversal agent

renal clearance

75
Q

Argatroban

A

based on L-arginine

asked on thrombin

Usual kit

Half-life 40-50 minutes

Liver metabolized-sacrum Q4 50

NO REVERSAL AGENT TO THE

76
Q

% blood volume is usually the trigger for transfusion and trauma

A

30%

77
Q

advantage with local reduced PRBCs

A

prevent CMV infection and transplant patient

Review febrile reaction

Cardiac surgery patient

Hello immunization

78
Q

Advantage of the washed PRBCs

A

prevention of allergic reactions

79
Q

define massive transfusion requirement

A

greater than 10 units of PRBCs in 24 hours

80
Q

how many units of PRBCs typically begins significant coagulopathy

A

10 units

BUT massive transfusion protocol is 111

81
Q

other than CMV what is the most common virus transmitted in transfusion

A

hepatitis B

82
Q

Workup for acute come office transfusion reaction

A

Stop transfusion
Fluids
Diuresis
Return units of blood bank with paperwork

Tests:
Direct Coombs test
Repeat crossmatch
Hemoglobin anemia
Hemoglobinuria
BUN/creatinine
Coagulation parameters
LDH hepatic Hepatoblobin
 blood cultures
83
Q

Most common nonhemolytic transfusion reaction

A

Febrile

Reaction to donor leukocyte or septic signs

84
Q

protective and decremental effects of transfusion

A

renal transplant-improved allograft

Colon cancer increased recurrence only cancer this is not found in his the cervix

Increase multiorgan failure

Leukocyte reduction improved for cardiac surgery only
Though-
Decreased febrile, and decreased hemolytic anemia decreased see him the risk

85
Q

FDA approved blood substitute available

A

no

86
Q

whichever greater risk of diffuse endothelial damage and consumptive coagulopathy theblunt or penetrating trauma

A

blunt when compared to more localized penetrating trauma

87
Q

effect of old blood and trauma patient’s

A

increased mortality greater than 14 days a storage

88
Q

storage time of FFP

A

one year

89
Q

FDA approved use for recombinant activated human factor VII a

A

hemophilia

COACH / CAM REVIEW (6 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions